The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Current treatment approaches in extranodal MZL & the need to enhance prognostication strategies
Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, Miami, FL, discusses current approaches to prognostication and treatment in extranodal marginal zone lymphoma (EMZL). Dr Alderuccio explains that patients are assessed using the GELF criteria used for follicular lymphoma (FL), due to a lack of specific biomarkers to determine front-line treatment in MZL. To conclude, Dr Alderuccio describes treatments that could be provided depending on whether a patient meets these criteria, and highlights a recent study exploring the efficacy of bendamustine-rituximab in this patient population. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
